Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza prevention. The approval makes AK0406 the first influenza-focused AFC candidate in China to progress into clinical development.

AK0406 is a next-generation, long-acting antiviral candidate discovered and developed by ArkBio. The molecule combines a highly potent antiviral small-molecule agent with an antibody Fc fragment through targeted conjugation, with the aim of delivering sustained protection before and after exposure and potentially offering therapeutic benefits.

This approach is intended to address the continuing need for effective influenza prevention, particularly during periods of high seasonal transmission. Preclinical studies indicate that AK0406 has potent and broad activity against both influenza A and influenza B viruses, while retaining immune effector activity and achieving prolonged systemic exposure. Its molecular design is intended to provide a balanced profile suitable for both influenza prophylaxis and treatment.

ArkBio is also advancing AK0406 through international clinical development. In February 2026, the company received authorization from an Australian Human Research Ethics Committee (HREC) to begin a Phase I study. Recruitment and dosing of healthy adult participants across all planned cohorts in Australia have been completed, and the study has subsequently moved into the follow-up stage.

Influenza continues to represent a substantial global public health burden. Existing prevention strategies rely heavily on seasonal vaccination, but these approaches have inherent challenges. These include the difficulty of accurately anticipating and matching circulating viral strains each year, the effects of ongoing antigenic drift, and lower levels of vaccine protection in certain vulnerable groups, including older adults and people with compromised immune systems. Consequently, significant unmet needs remain in influenza prevention.

ArkBio plans to work closely with China’s Center for Drug Evaluation (CDE) to support the continued clinical development of AK0406 in China while completing follow-up activities associated with the Phase I study in Australia. Through a coordinated development strategy spanning China and international markets, the company intends to advance the program efficiently and ultimately develop a safe, effective, and convenient option for influenza prevention worldwide.

Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States.

During its presentation at Biotech Showcase 2026, the company outlined a forward-looking antiviral approach centered on Xafty, a broad-spectrum therapeutic designed to combat multiple viruses. Marking a decisive shift in focus, the company stated that preparations in Vietnam have been finalized and that efforts are now moving to the U.S. market.

A Long-Awaited Broad-Spectrum Antiviral
A major focus of the announcement was the clinical framework developed in partnership with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD).

Dr. Smith, an internationally recognized infectious disease specialist who previously headed the U.S. government’s ACTIV-2 COVID-19 clinical trials, described the current public health landscape in the U.S. as a “tripledemic” driven by influenza, RSV, and emerging COVID-19 strains—conditions that currently lack a single, comprehensive treatment solution.

Commenting on the trial design, Dr. Smith explained that Xafty offers the potential to address several viral infections simultaneously. He noted that the innovative “basket trial” model enables efficient evaluation across multiple viruses and represents a practical response to the ongoing multi-virus challenge. Emphasizing urgency, he stressed the importance of accelerating clinical progress to bring new treatment options to patients as quickly as possible.

“One Drug, Two Tracks”: A Global Strategy
Hyundai Bioscience also introduced its “One Drug, Two Tracks” development model, which deploys Xafty across two distinct clinical pathways:

By advancing the same drug in different viral settings, the company aims to demonstrate Xafty’s wide-ranging antiviral capability, spanning both mosquito-transmitted and respiratory infections. The strategy mirrors the versatility of modern antibiotics that are effective against multiple bacterial strains.

Jason Kim, CEO of Hyundai Bioscience USA, noted that discussions at the showcase confirmed strong alignment between the company’s clinical strategy and unmet needs within the U.S. healthcare system. He added that all preparations are in place and that the company is ready to promptly file its Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Looking Ahead: A New Era in Antiviral Treatment
The presentation concluded with a forward-looking vision for global health. Dr. Smith observed that antiviral development has historically been reactive, focused on chasing evolving variants. He expressed confidence that a preventive, broad-spectrum approach could redefine the field, positioning this clinical trial as a potential milestone in the development of antivirals capable of targeting multiple viruses with a single therapy.